StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 07 May 2026 08:30:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Oragenics signs letter of intent to license blood purification technology http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html <p>Oragenics Inc. (NYSE American: OGEN) signed a letter of intent to license CardioDialysis technology from Sigyn Therapeutics Inc. (OTCQB: SIGY) for treating traumatic brain injury and other chronic neurodegenerative diseases, according to a company statement.</p><p>The proposed exclusive license would allow Oragenics to develop and commercialize the blood purification technology, which removes inflammatory and pathogenic molecules from the bloodstream. The company plans to combine this approach with its existing ONP-002 neurosteroid treatment, currently in Phase IIa clinical trials for concussion and mild traumatic brain injury.</p><p>Under the proposed terms, Oragenics would issue 3.25 million shares of restricted preferred stock to Sigyn, convertible http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html Thu, 07 May 2026 08:30:37 -0400 OGEN SIGY SIGYD Oragenics signs letter of intent to license blood purification technology http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html <p>Oragenics Inc. (NYSE American: OGEN) signed a letter of intent to license CardioDialysis technology from Sigyn Therapeutics Inc. (OTCQB: SIGY) for treating traumatic brain injury and other chronic neurodegenerative diseases, according to a company statement.</p><p>The proposed exclusive license would allow Oragenics to develop and commercialize the blood purification technology, which removes inflammatory and pathogenic molecules from the bloodstream. The company plans to combine this approach with its existing ONP-002 neurosteroid treatment, currently in Phase IIa clinical trials for concussion and mild traumatic brain injury.</p><p>Under the proposed terms, Oragenics would issue 3.25 million shares of restricted preferred stock to Sigyn, convertible http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html Thu, 07 May 2026 08:30:37 -0400 OGEN SIGY SIGYD Oragenics signs letter of intent to license blood purification technology http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html <p>Oragenics Inc. (NYSE American: OGEN) signed a letter of intent to license CardioDialysis technology from Sigyn Therapeutics Inc. (OTCQB: SIGY) for treating traumatic brain injury and other chronic neurodegenerative diseases, according to a company statement.</p><p>The proposed exclusive license would allow Oragenics to develop and commercialize the blood purification technology, which removes inflammatory and pathogenic molecules from the bloodstream. The company plans to combine this approach with its existing ONP-002 neurosteroid treatment, currently in Phase IIa clinical trials for concussion and mild traumatic brain injury.</p><p>Under the proposed terms, Oragenics would issue 3.25 million shares of restricted preferred stock to Sigyn, convertible http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html Thu, 07 May 2026 08:30:37 -0400 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Press+Releases/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html <p align="justify"><i>The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier</i></p> <p align="justify"><strong>Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum http://www.streetinsider.com/Globe+Newswire/Oragenics+Signs+Letter+of+Intent+to+License+CardioDialysis%E2%84%A2+Technology+from+Sigyn+Therapeutics+to+Target+TBI-Induced+Systemic+Inflammation/26449135.html Thu, 07 May 2026 08:30:00 -0400 O.00978679 O.37300898 OGEN SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html <p>SAN DIEGO, CA - April 2, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). </p><p>Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinsons disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players. </p><p>While http://www.streetinsider.com/Press+Releases/Sigyn+Therapeutics+Launches+Initiative+to+Evaluate+Emerging+Medical+Technologies+in+Former+NFL+Players+at+Risk+of+CTE/26262744.html Thu, 02 Apr 2026 08:00:00 -0400 A.12512883 A.12732878 O.03960735 O.05048523 O.37300898 SIGY SIGYD Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html <p>SAN DIEGO, CA - March 24, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy. </p><p>On March 21, Scientific American published an article entitled; Brains Protective http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html Tue, 24 Mar 2026 08:00:00 -0400 A.12512883 A.60003683 O.01075659 O.05048523 O.37300898 SIGY SIGYD Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html <p>SAN DIEGO, CA - March 24, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy. </p><p>On March 21, Scientific American published an article entitled; Brains Protective http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html Tue, 24 Mar 2026 08:00:00 -0400 A.12512883 A.60003683 O.01075659 O.05048523 O.37300898 SIGY SIGYD Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html <p>SAN DIEGO, CA - March 24, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy. </p><p>On March 21, Scientific American published an article entitled; Brains Protective http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html Tue, 24 Mar 2026 08:00:00 -0400 A.12512883 A.60003683 O.01075659 O.05048523 O.37300898 SIGY SIGYD Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html <p>SAN DIEGO, CA - March 24, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy. </p><p>On March 21, Scientific American published an article entitled; Brains Protective http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html Tue, 24 Mar 2026 08:00:00 -0400 A.12512883 A.60003683 O.01075659 O.05048523 O.37300898 SIGY SIGYD Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html <p>SAN DIEGO, CA - March 24, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), developer of CardioDialysis(TM), a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy. </p><p>On March 21, Scientific American published an article entitled; Brains Protective http://www.streetinsider.com/Press+Releases/Scientific+American+Highlights+Scientific+Discovery+That+Supports+the+Potential+Use+of+CardioDialysis%28TM%29+to+Treat+Neuroinflammatory+Diseases/26206728.html Tue, 24 Mar 2026 08:00:00 -0400 A.12512883 A.60003683 O.01075659 O.05048523 O.37300898 SIGY SIGYD